Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide Dose-Response in Japanese T2D
NCT01001104Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2009
- Primary completion
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 weeks. Started Oct 2009; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01001104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001104.